AIGH Capital Management LLC Sells 698,635 Shares of Theratechnologies Inc. (NASDAQ:THTX)

AIGH Capital Management LLC reduced its position in Theratechnologies Inc. (NASDAQ:THTX) by 18.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,026,569 shares of the company’s stock after selling 698,635 shares during the period. Theratechnologies accounts for approximately 1.7% of AIGH Capital Management LLC’s portfolio, making the stock its 21st largest holding. AIGH Capital Management LLC owned approximately 6.58% of Theratechnologies worth $5,478,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in THTX. Harbour Investments Inc. raised its position in shares of Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after purchasing an additional 14,655 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Theratechnologies in the fourth quarter worth about $27,000. JPMorgan Chase & Co. purchased a new position in shares of Theratechnologies during the 4th quarter valued at $33,000. Wealthspire Advisors LLC raised its holdings in shares of Theratechnologies by 39.0% in the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Theratechnologies in the 4th quarter worth about $40,000.

Theratechnologies Price Performance

Shares of NASDAQ:THTX opened at $1.50 on Friday. The company has a market capitalization of $68.97 million, a PE ratio of -15.00 and a beta of 1.24. Theratechnologies Inc. has a 1-year low of $1.08 and a 1-year high of $2.18. The business has a fifty day moving average price of $1.64 and a 200-day moving average price of $1.49.

Wall Street Analysts Forecast Growth

Separately, Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.